A rare and aggressive form of liver cancer has long resisted immunotherapy, a treatment that helps the body's own immune system attack cancer cells. Now, researchers have identified a potential way to overcome that resistance using an FDA-approved drug that is already available for another medical condition.
The findings suggest a possible new treatment strategy for fibrolamellar carcinoma, a rare liver cancer that primarily affects children and young adults.
Fibrolamellar carcinoma makes up about 2% of all liver cancer cases. There is currently no cure, and the disease is often discovered only after it has spread to other parts of the body, leaving many patients with limited treatment options and poor survival prospects.
How Fibrolamellar Carcinoma Evades the Immune System
The study, published in the journal Gastroenterology, sheds light on why immunotherapy has struggled against this cancer.
